Clinical Trial Search

Primary: Percentage of Participants Who Experience an Adverse Event (AE) — 98.1; 100.0 Percentage of Participants

Primary: Changes in 18F-fluciclovine PET Scan for Patients With mCRPC on Treatment With Life Prolonging Therapies — 5; 0; 3; 0 Participants

Primary: Change From Baseline in AN Count at Week 16: Placebo-Controlled Period — -5.9; -4.1; -5.6 count of abscess and inflammatory nodule — p=0.7841

Primary: Cure Rate (CR) Against T. Trichiura — 17.5; 50.0; 83.3; 84.6 percentage of participants cured (%)

Primary: Change in WAB-AQ — 3.0; 2.8 score on a scale — p=<.05

Primary: Overall Response — 0; 1; 1; 0 Participants

Primary: Efficacy by UHDRS-TMS — -1.23; 0.84; 8.91 score on a scale/year

Primary: Percentage of Participants With Hepatitis B Surface Antigen (HBsAg) Loss at 24 Weeks Post-End of Treatment (EOT) — 0; 0; 6.7; 3.3 percentage of participants

Primary: Geometric Mean Titer (GMT) of Bavarian Nordic's (BN) Plaque Reduction Neutralizing Antibody Titer (PRNT) Assay in Groups A and B — 10.8; 30.2 titer

Primary: Pathologic Complete Response Rate — 9 Participants

Primary: Pulmonary Function — 3.59; 3.77 L

Primary: Change From Baseline at Week 6 in the Positive and Negative Syndrome Scale (PANSS) Total Score — -13.5; -14.7; -16.5 units on a scale — p==0.1765

Primary: Change in MMTT (Mixed Meal Tolerance Test) 90 Min C-peptide — -1.23; -0.62 ng/mL

Primary: Progression-free Survival (PFS) — 8.2; 8.1 Months — p=0.4698

Primary: Proportion of Volunteers With an Increase of Anti-tetanus Neutralizing Antibody Titers Over Protective Level — 56; 61; 29; 48 Participants